In a phase 3 trial, #culmerciclib plus #fulvestrant improved PFS and response rates versus fulvestrant alone in pretreated #HRPositive, #HER2Negative advanced #BreastCancer, supporting dual CDK2/4/6 targeting to overcome resistance.

#OpenAccess in #STTT: doi.org/10.1038/s413...

A phase 3 #ClinicalTrial evaluating the efficacy of #Culmerciclib + #Fulvestrant in HR-positive, HER2-negative advanced #BreastCancer demonstrated improved progression-free survival and a manageable safety profile.

#STTT #OpenAccess: doi.org/10.1038/s413...

#Culmerciclib combined with #fulvestrant significantly improved #ProgressionFreeSurvival and response rate in pretreated HR‑positive, #HER2‑negative advanced #BreastCancer, supporting combined CDK2/4/6 blockade as a promising therapeutic strategy.

#STTT: doi.org/10.1038/s413...

A randomized, double-blind, phase 3 #ClinicalTrial evaluating the efficacy of #Culmerciclib + #Fulvestrant in HR-positive, HER2-negative #AdvancedBreastCancer showed improved progression-free survival & tolerable safety.

#STTT #OpenAccess: doi.org/10.1038/s413...

La NMPA aprueba las cápsulas de Culmerciclib para su comercialización en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#NMPA #AprobaciónDeMedicamentos #Culmerciclib #CáncerDeMama #HRpositivo #HER2negativo #Oncología #InnovaciónFarmacéutica #ChinaPharma